{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:36:01Z","timestamp":1782513361840,"version":"3.54.5"},"reference-count":90,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institute of Health (NIH)","doi-asserted-by":"publisher","award":["R01CA174861"],"award-info":[{"award-number":["R01CA174861"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institute of Health (NIH)","doi-asserted-by":"publisher","award":["R01CA228760"],"award-info":[{"award-number":["R01CA228760"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institute of Health (NIH)","doi-asserted-by":"publisher","award":["R01CA276179"],"award-info":[{"award-number":["R01CA276179"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institute of Health (NIH)","doi-asserted-by":"publisher","award":["P50 CA116201"],"award-info":[{"award-number":["P50 CA116201"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institute of Health (NIH)","doi-asserted-by":"publisher","award":["R01CA236948"],"award-info":[{"award-number":["R01CA236948"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Adjuvant systemic therapies effectively reduce the risk of breast cancer recurrence and metastasis, but therapy resistance can develop in some patients due to breast cancer stem cells (BCSCs). Oncolytic adenovirus (OAd) represents a promising therapeutic approach as it can specifically target cancer cells. However, its potential to target BCSCs remains unclear. Here, we evaluated a Cox-2 promoter-controlled, Ad5\/3 fiber-modified OAd designed to encode the human sodium iodide symporter (hNIS) in breast cancer models. To confirm the potential of OAds to target BCSCs, we employed BCSC-enriched estrogen receptor-positive (ER+) paclitaxel-resistant (TaxR) cells and tumorsphere assays. OAd-hNIS demonstrated significantly enhanced binding and superior oncolysis in breast cancer cells, including ER+ cells, while exhibiting no activity in normal mammary epithelial cells. We observed improved NIS expression as the result of adenovirus death protein deletion. OAd-hNIS demonstrated efficacy in targeting TaxR BCSCs, exhibiting superior killing and hNIS expression compared to the parental cells. Our vector was capable of inhibiting tumorsphere formation upon early infection and reversing paclitaxel resistance in TaxR cells. Importantly, OAd-hNIS also destroyed already formed tumorspheres seven days after their initiation. Overall, our findings highlight the promise of OAd-hNIS as a potential tool for studying and targeting ER+ breast cancer recurrence and metastasis.<\/jats:p>","DOI":"10.3390\/v16040567","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T08:27:52Z","timestamp":1712305672000},"page":"567","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2807-4410","authenticated-orcid":false,"given":"Sacha","family":"Robert","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4348-6165","authenticated-orcid":false,"given":"Natasha Ivelisse","family":"Roman Ortiz","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-1405","authenticated-orcid":false,"given":"Christopher J.","family":"LaRocca","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5038-6875","authenticated-orcid":false,"given":"Julie Hanson","family":"Ostrander","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Davydova","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Institute of Molecular Virology, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14740\/jocmr4398","article-title":"Percentage of Hormone Receptor Positivity in Breast Cancer Provides Prognostic Value: A Single-Institute Study","volume":"13","author":"Sleightholm","year":"2021","journal-title":"J. Clin. Med. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jsbmb.2015.05.005","article-title":"From Bench to Bedside: What Do We Know about Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer?","volume":"153","author":"Wu","year":"2015","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","volume":"377","author":"Pan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years after Diagnosis of Oestrogen Receptor-Positive Breast Cancer: ATLAS, a Randomised Trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet Lond. Engl."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., Darby, S., McGale, P., Pan, H.C., and Taylor, C. (2011). Relevance of Breast Cancer Hormone Receptors and Other Factors to the Efficacy of Adjuvant Tamoxifen: Patient-Level Meta-Analysis of Randomised Trials. Lancet Lond. Engl., 378, 771\u2013784.","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.molonc.2016.09.009","article-title":"Tumor Cell Dormancy","volume":"11","author":"Gomis","year":"2017","journal-title":"Mol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ajpath.2011.03.005","article-title":"The Role of Breast Cancer Stem Cells in Metastasis and Therapeutic Implications","volume":"179","author":"Popov","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41523-021-00337-2","article-title":"Ganitumab and Metformin plus Standard Neoadjuvant Therapy in Stage 2\/3 Breast Cancer","volume":"7","author":"Yee","year":"2021","journal-title":"npj Breast Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.12703\/r\/10-2","article-title":"Recent Advances in Neoadjuvant Therapy for Breast Cancer","volume":"10","author":"Potter","year":"2021","journal-title":"Fac. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Rahman, M.M., and McFadden, G. (2021). Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy. Cancers, 13.","DOI":"10.3390\/cancers13215452"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"19976","DOI":"10.18632\/oncotarget.5116","article-title":"Going Viral: A Review of Replication-Selective Oncolytic Adenoviruses","volume":"6","author":"Larson","year":"2015","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic Viruses for Cancer Immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Peter, M., and K\u00fchnel, F. (2020). Oncolytic Adenovirus in Cancer Immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12113354"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"803050","DOI":"10.3389\/fonc.2021.803050","article-title":"Clinical Trials of Oncolytic Viruses in Breast Cancer","volume":"11","author":"Carter","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-physiol-022516-034125","article-title":"The Sodium\/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications","volume":"79","author":"Ravera","year":"2017","journal-title":"Annu. Rev. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1089\/hum.2012.047","article-title":"Characterization of Infectivity-Enhanced Conditionally Replicating Adenovectors for Prostate Cancer Radiovirotherapy","volume":"23","author":"Oneal","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.omto.2021.03.002","article-title":"Cancer Imaging and Therapy Utilizing a Novel NIS-Expressing Adenovirus: The Role of Adenovirus Death Protein Deletion","volume":"20","author":"Robertson","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1002\/cncr.11437","article-title":"Elevated Expression of Cyclooxygenase-2 Is a Negative Prognostic Factor for Disease Free Survival and Overall Survival in Patients with Breast Carcinoma","volume":"97","author":"Denkert","year":"2003","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1099\/vir.0.83142-0","article-title":"Species B Adenovirus Serotypes 3, 7, 11 and 35 Share Similar Binding Sites on the Membrane Cofactor Protein CD46 Receptor","volume":"88","author":"Fleischli","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 Is a Receptor for Adenovirus Serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/PAI.0b013e31821a0be9","article-title":"CD46 Expression Is an Unfavorable Prognostic Factor in Breast Cancer Cases","volume":"19","author":"Maciejczyk","year":"2011","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e2014408118","DOI":"10.1073\/pnas.2014408118","article-title":"Interplay between Desmoglein2 and Hypoxia Controls Metastasis in Breast Cancer","volume":"118","author":"Chang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5619472","DOI":"10.1155\/2017\/5619472","article-title":"Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment","volume":"2017","author":"Aponte","year":"2017","journal-title":"Stem Cells Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1089\/scd.2012.0613","article-title":"Strategies for Isolating and Enriching Cancer Stem Cells: Well Begun Is Half Done","volume":"22","author":"Duan","year":"2013","journal-title":"Stem Cells Dev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1158\/1541-7786.MCR-18-0410","article-title":"Taxol Induces Brk-Dependent Prosurvival Phenotypes in TNBC Cells through an AhR\/GR\/HIF-Driven Signaling Axis","volume":"16","author":"Ma","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1038\/s41388-021-01871-w","article-title":"PELP1\/SRC-3-Dependent Regulation of Metabolic PFKFB Kinases Drives Therapy Resistant ER+ Breast Cancer","volume":"40","author":"Truong","year":"2021","journal-title":"Oncogene"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective Identification of Tumorigenic Breast Cancer Cells","volume":"100","author":"Wicha","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.7150\/ijbs.76187","article-title":"Targeting Breast Cancer Stem Cells","volume":"19","author":"Zhang","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1089\/104303403766682205","article-title":"Replicative Oncolytic Adenoviruses in Multimodal Cancer Regimens","volume":"14","author":"Post","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncponc0736","article-title":"Clinical Trial Results with Oncolytic Virotherapy: A Century of Promise, a Decade of Progress","volume":"4","author":"Liu","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.surg.2015.01.006","article-title":"Oncolytic Adenovirus Expressing Interferon Alpha in a Syngeneic Syrian Hamster Model for the Treatment of Pancreatic Cancer","volume":"157","author":"LaRocca","year":"2015","journal-title":"Surgery"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Farrera-Sal, M., Fillat, C., and Alemany, R. (2020). Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses. Cancers, 12.","DOI":"10.3390\/cancers12041034"},{"key":"ref_34","first-page":"63","article-title":"Promising Oncolytic Agents for Metastatic Breast Cancer Treatment","volume":"4","author":"Cody","year":"2015","journal-title":"Oncolytic Virotherapy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients with Chemotherapy Refractory Cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/sj.cgt.7701080","article-title":"A Phase I Trial of Intravenous Infusion of ONYX-015 and Enbrel in Solid Tumor Patients","volume":"14","author":"Nemunaitis","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/mt.2009.262","article-title":"A Phase I Study of Telomerase-Specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors","volume":"18","author":"Nemunaitis","year":"2010","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","article-title":"A Phase 1 Dose Escalation Study of the Oncolytic Adenovirus Enadenotucirev, Administered Intravenously to Patients with Epithelial Solid Tumors (EVOLVE)","volume":"7","author":"Machiels","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e003255","DOI":"10.1136\/jitc-2021-003255","article-title":"Phase I, Multicenter, Open-Label Study of Intravenous VCN-01 Oncolytic Adenovirus with or without Nab-Paclitaxel plus Gemcitabine in Patients with Advanced Solid Tumors","volume":"10","author":"Macarulla","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/gt.2008.179","article-title":"A Phase I Trial of Intratumoral Administration of Recombinant Oncolytic Adenovirus Overexpressing HSP70 in Advanced Solid Tumor Patients","volume":"16","author":"Li","year":"2009","journal-title":"Gene Ther."},{"key":"ref_41","unstructured":"Lim, B. (2024, April 01). Binary Oncolytic Adenovirus in Combination with HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (VISTA). NIH U.S. National Library of Medicine. ClinicalTrials.gov Identifier number NCT03740256. 2018, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03740256."},{"key":"ref_42","unstructured":"Chang, J. (2024, April 01). SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (STOMP). NIH U.S. National Library of Medicine. ClinicalTrials.gov Identifier number NCT03004183. 2016, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/study\/NCT03004183."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and Antitumor T-Cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1078057","DOI":"10.1080\/2162402X.2015.1078057","article-title":"Oncolytic Virotherapy for Treatment of Breast Cancer, Including Triple-Negative Breast Cancer","volume":"5","author":"Bramante","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.18632\/oncotarget.2901","article-title":"Immunological Data from Cancer Patients Treated with Ad5\/3-E2F-\u039424-GMCSF Suggests Utility for Tumor Immunotherapy","volume":"6","author":"Hemminki","year":"2015","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2011.113","article-title":"Immunological Effects of Low-Dose Cyclophosphamide in Cancer Patients Treated with Oncolytic Adenovirus","volume":"19","author":"Cerullo","year":"2011","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/ijc.26216","article-title":"Integrin Targeted Oncolytic Adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for Treatment of Patients with Advanced Chemotherapy Refractory Solid Tumors","volume":"130","author":"Pesonen","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-09-3167","article-title":"Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors","volume":"16","author":"Nokisalmi","year":"2010","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1089\/hum.2020.078","article-title":"LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor \u03b2 Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models","volume":"31","author":"Xu","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/bcr2342","article-title":"Construction of an MUC-1 Promoter Driven, Conditionally Replicating Adenovirus That Expresses the Sodium Iodide Symporter for Gene Therapy of Breast Cancer","volume":"11","author":"Trujillo","year":"2009","journal-title":"Breast Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.omto.2021.12.013","article-title":"Superior Infectivity of the Fiber Chimeric Oncolytic Adenoviruses Ad5\/35 and Ad5\/3 over Ad5-Delta-24-RGD in Primary Glioma Cultures","volume":"24","author":"Stepanenko","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1158\/0008-5472.CAN-04-0064","article-title":"Infectivity-Enhanced Cyclooxygenase-2-Based Conditionally Replicative Adenoviruses for Esophageal Adenocarcinoma Treatment","volume":"64","author":"Davydova","year":"2004","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.amjsurg.2012.02.016","article-title":"Generation of a Novel, Cyclooxygenase-2-Targeted, Interferon-Expressing, Conditionally Replicative Adenovirus for Pancreatic Cancer Therapy","volume":"204","author":"Armstrong","year":"2012","journal-title":"Am. J. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1001\/jama.1946.02870490016004","article-title":"Radioactive Iodine Therapy; Effect on Functioning Metastases of Adenocarcinoma of the Thyroid","volume":"132","author":"Seidlin","year":"1946","journal-title":"J. Am. Med. Assoc."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"T193","DOI":"10.1530\/ERC-21-0177","article-title":"The Sodium Iodide Symporter (NIS): Novel Applications for Radionuclide Imaging and Treatment","volume":"28","author":"Spitzweg","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/mt.2008.172","article-title":"Phase I Study of Noninvasive Imaging of Adenovirus-Mediated Gene Expression in the Human Prostate","volume":"16","author":"Barton","year":"2008","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/cgt.2013.4","article-title":"Effect of Increased Viral Replication and Infectivity Enhancement on Radioiodide Uptake and Oncolytic Activity of Adenovirus Vectors Expressing the Sodium Iodide Symporter","volume":"20","author":"Oneal","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.omto.2019.10.002","article-title":"Dual-Isotope SPECT Imaging with NIS Reporter Gene and Duramycin to Visualize Tumor Susceptibility to Oncolytic Virus Infection","volume":"15","author":"Zhang","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1158\/1078-0432.CCR-04-1636","article-title":"In Vivo Radioiodide Imaging and Treatment of Breast Cancer Xenografts after MUC1-Driven Expression of the Sodium Iodide Symporter","volume":"11","author":"Dwyer","year":"2005","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/cgt.2008.6","article-title":"Targeting Sodium\/Iodide Symporter Gene Expression for Estrogen-Regulated Imaging and Therapy in Breast Cancer","volume":"15","author":"Quintanilla","year":"2008","journal-title":"Cancer Gene Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"E1435","DOI":"10.1210\/jc.2010-2373","article-title":"Telomerase-Driven Expression of the Sodium Iodide Symporter (NIS) for in Vivo Radioiodide Treatment of Cancer: A New Broad-Spectrum NIS-Mediated Antitumor Approach","volume":"96","author":"Miranda","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_63","first-page":"3484","article-title":"Adenovirus-Mediated Transfer of the Thyroid Sodium\/Iodide Symporter Gene into Tumors for a Targeted Radiotherapy","volume":"60","author":"Boland","year":"2000","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1349-7006.2009.01407.x","article-title":"In Vivo Bioimaging Tracks Conditionally Replicative Adenoviral Replication and Provides an Early Indication of Viral Antitumor Efficacy","volume":"101","author":"Davydova","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/viro.2002.1772","article-title":"Overexpression of the ADP (E3-11.6K) Protein Increases Cell Lysis and Spread of Adenovirus","volume":"305","author":"Doronin","year":"2003","journal-title":"Virology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.gt.3301389","article-title":"Polymer-Coated Adenovirus Permits Efficient Retargeting and Evades Neutralising Antibodies","volume":"8","author":"Fisher","year":"2001","journal-title":"Gene Ther."},{"key":"ref_67","first-page":"6359","article-title":"Selective Replication and Oncolysis in P53 Mutant Tumors with ONYX-015, an E1B-55kD Gene-Deleted Adenovirus, in Patients with Advanced Head and Neck Cancer: A Phase II Trial","volume":"60","author":"Nemunaitis","year":"2000","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.4161\/cbt.26043","article-title":"Oncolytic Adenovirus Encoding Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Inhibits the Growth and Metastasis of Triple-Negative Breast Cancer","volume":"14","author":"Zhu","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/jcmm.16113","article-title":"Anti-Tumour Effects of a Dual Cancer-Specific Oncolytic Adenovirus on Breast Cancer Stem Cells","volume":"25","author":"Li","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1756-9966-31-51","article-title":"Oncolytic Adenovirus Armed with IL-24 Inhibits the Growth of Breast Cancer in Vitro and in Vivo","volume":"31","author":"Zhu","year":"2012","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1089\/104303402760293574","article-title":"New Oncolytic Adenoviruses with Hypoxia- and Estrogen Receptor-Regulated Replication","volume":"13","author":"Pihalja","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/0008-5472.CAN-07-5288","article-title":"Tissue-Specific Promoters Active in CD44+CD24-\/Low Breast Cancer Cells","volume":"68","author":"Bauerschmitz","year":"2008","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1172\/JCI9180","article-title":"Selectivity of a Replication-Competent Adenovirus for Human Breast Carcinoma Cells Expressing the MUC1 Antigen","volume":"106","author":"Kurihara","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ymthe.2004.07.023","article-title":"Oncolytic Effects of Adenovirus Mutant Capable of Replicating in Hypoxic and Normoxic Regions of Solid Tumor","volume":"10","author":"Cho","year":"2004","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-08-1360","article-title":"Antitumor Activity of an Oncolytic Adenoviral-CD40 Ligand (CD154) Transgene Construct in Human Breast Cancer Cells","volume":"15","author":"Gomes","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_76","first-page":"237","article-title":"Incorporating the Survivin Promoter in an Infectivity Enhanced CRAd-Analysis of Oncolysis and Anti-Tumor Effects In Vitro and In Vivo","volume":"27","author":"Zhu","year":"2005","journal-title":"Int. J. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1006\/mthe.2002.0680","article-title":"Adenoviral Vectors with E1A Regulated by Tumor-Specific Promoters Are Selectively Cytolytic for Breast Cancer and Melanoma","volume":"6","author":"Zhang","year":"2002","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13193-014-0290-y","article-title":"Role of Cyclooxygenase 2 (COX-2) in Prognosis of Breast Cancer","volume":"5","author":"Jana","year":"2014","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Gavrikova, T., Nakamura, N., Davydova, J., Antonarakis, E.S., and Yamamoto, M. (2023). Infectivity-Enhanced, Conditionally Replicative Adenovirus for COX-2-Expressing Castration-Resistant Prostate Cancer. Viruses, 15.","DOI":"10.3390\/v15040901"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"8556","DOI":"10.1245\/s10434-021-10382-7","article-title":"Interferon Alpha-Expressing Oncolytic Adenovirus for Treatment of Esophageal Adenocarcinoma","volume":"28","author":"LaRocca","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"860","DOI":"10.18632\/oncotarget.1018","article-title":"Potent Antitumor Activity of Oncolytic Adenovirus Expressing Beclin-1 via Induction of Autophagic Cell Death in Leukemia","volume":"4","author":"Tong","year":"2013","journal-title":"Oncotarget"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/jnci\/djm102","article-title":"Examination of the Therapeutic Potential of Delta-24-RGD in Brain Tumor Stem Cells: Role of Autophagic Cell Death","volume":"99","author":"Jiang","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"29346","DOI":"10.18632\/oncotarget.8830","article-title":"GP73-Regulated Oncolytic Adenoviruses Possess Potent Killing Effect on Human Liver Cancer Stem-like Cells","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/jcmm.12397","article-title":"Targeting Lung Cancer Stem-like Cells with TRAIL Gene Armed Oncolytic Adenovirus","volume":"19","author":"Yang","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1158\/1078-0432.CCR-13-0742","article-title":"A Genetically Engineered Oncolytic Adenovirus Decoys and Lethally Traps Quiescent Cancer Stem-like Cells in S\/G2\/M Phases","volume":"19","author":"Yano","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"791696","DOI":"10.3389\/fonc.2021.791696","article-title":"The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting","volume":"11","author":"Walker","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.onc.1203412","article-title":"Selective Activation of NF-Kappa B Subunits in Human Breast Cancer: Potential Roles for NF-Kappa B2\/P52 and for Bcl-3","volume":"19","author":"Cogswell","year":"2000","journal-title":"Oncogene"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0163-7827(03)00037-7","article-title":"Recent Advances in Molecular Biology and Physiology of the Prostaglandin E2-Biosynthetic Pathway","volume":"43","author":"Murakami","year":"2004","journal-title":"Prog. Lipid Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1038\/sj.mt.6300300","article-title":"Oncolytic Adenoviruses Kill Breast Cancer Initiating CD44+CD24-\/Low Cells","volume":"15","author":"Eriksson","year":"2007","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.6004\/jnccn.2020.7598","article-title":"Use of 18F-FDG PET\/CT as an Initial Staging Procedure for Stage II\u2013III Breast Cancer: A Multicenter Value Analysis","volume":"18","author":"Hyland","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/4\/567\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:23:47Z","timestamp":1760106227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/4\/567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":90,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["v16040567"],"URL":"https:\/\/doi.org\/10.3390\/v16040567","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]}}}